Drug intelligence / Profile preview

HC104

Development stage: Preclinical
Lead developer: HebeCell
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

HC104 is an experimental, preclinical-stage cell therapy being developed by HebeCell for the treatment of solid tumors, specifically gastric and lung cancers. The therapy is based on HebeCell's proprietary induced pluripotent stem cell (iPSC) platform, which is used to generate Chimeric Antigen Receptor (CAR)-modified Natural Killer (NK) cells (PSC-CAR-NK). This approach is designed to provide a standardized, off-the-shelf immunotherapy that combines the targeted specificity of a CAR with the potent, innate anti-tumor effector functions of NK cells.

Beyond the preview

Go deeper on HC104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HC104.

Explore the full profile